Bliss GVS Pharma
Ticker > Company >

Bliss GVS Pharma share price

Bliss GVS Pharma Ltd.

NSE: BLISSGVS BSE: 506197 SECTOR: Pharmaceuticals & Drugs  63k   227   20

161.15
-8.69 (-5.12%)
NSE: 20 Dec 04:02 PM

Price Summary

Today's High

₹ 174.19

Today's Low

₹ 160.1

52 Week High

₹ 179.8

52 Week Low

₹ 92.15

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 1697.98 Cr.

Enterprise Value

₹ 1594.29 Cr.

No. of Shares

10.54 Cr.

P/E

37.14

P/B

1.66

Face Value

₹ 1

Div. Yield

0.31 %

Book Value (TTM)

₹  97.26

CASH

₹ 169.32 Cr.

DEBT

₹ 65.63 Cr.

Promoter Holding

34.82 %

EPS (TTM)

₹  4.34

Sales Growth

1.19%

ROE

5.31 %

ROCE

7.36%

Profit Growth

-40.75 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Bliss GVS Pharma Ltd.

Alain Gvither Lonart Rectol PARAFEN Vomitin Slipizem tacy Imazole Ecozole Vagikit Lofnac Comit Zinvite Clomain Alvite FUNBACT SOAP TODAY Instant Head Sanitizer SOFTNESS Mosquito Repellant Cream VAGID Dusting powder ALLSOFT

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year1.19%
3 Year9.16%
5 Year7.25%

Profit Growth

1 Year-40.75%
3 Year-9.13%
5 Year-7.41%

ROE%

1 Year5.31%
3 Year8.88%
5 Year10.09%

ROCE %

1 Year7.36%
3 Year11.64%
5 Year12.94%

Debt/Equity

0.0669

Price to Cash Flow

13.48

Interest Cover Ratio

13.1007

CFO/PAT (5 Yr. Avg.)

1.06520258986482

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 34.82 0.00
Jun 2024 34.90 0.00
Mar 2024 34.97 0.00
Dec 2023 34.97 0.00
Sep 2023 35.06 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 13.1007.
  • Company has a healthy liquidity position with current ratio of 6.5893.
  • The company has a good cash flow management; CFO/PAT stands at 1.06520258986482.

 Limitations

  • The company has shown a poor profit growth of -9.13242614237328% for the Past 3 years.
  • The company has shown a poor revenue growth of 9.15678375988394% for the Past 3 years.
  • Company has high debtor days of 240.7079.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 171.32 161.34 163.82 148.96 182.65
Total Expenditure 129.01 132.68 138.67 122.22 157.27
Operating Profit 42.31 28.66 25.15 26.74 25.38
Other Income 10.61 7.9 8.46 6.84 8.35
Interest 1.18 1.79 1.53 1.17 3.45
Depreciation 5.68 6.25 6.23 6.26 6.4
Exceptional Items 0 0 -41.09 0 0
Profit Before Tax 46.07 28.52 -15.23 26.15 23.89
Tax 12.18 7.8 -3.77 6.73 6.85
Profit After Tax 33.89 20.72 -11.46 19.42 17.04
Adjusted EPS (Rs) 3.25 1.98 -1.09 1.85 1.62

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 441.95 465.51 636.36 598.34 605.46
Total Expenditure 341.78 374.05 527.16 508.18 499.94
Operating Profit 100.17 91.46 109.2 90.16 105.52
Other Income 37 19.41 32.63 50.77 35.15
Interest 6.62 5.92 4.32 10.06 5.81
Depreciation 8.83 13.76 13.85 15.17 23.52
Exceptional Items 0 0 2.75 0 -41.09
Profit Before Tax 121.71 91.19 126.4 115.69 70.26
Tax 29.38 23.69 33.74 30.21 19.61
Net Profit 92.33 67.5 92.66 85.48 50.64
Adjusted EPS (Rs.) 8.95 6.54 8.94 8.21 4.84

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 10.31 10.31 10.37 10.42 10.47
Total Reserves 672.63 745.33 841.06 926.58 977.97
Borrowings 35.55 32.49 23.22 40.69 35.1
Other N/C liabilities 11.12 11.38 12.48 8.65 7.59
Current liabilities 125.5 146.11 192.83 153.36 117.31
Total Liabilities 855.11 945.62 1079.96 1139.69 1148.44
Assets
Net Block 178.86 174.1 224.31 324.82 329.95
Capital WIP 0 2.39 22.15 2.8 7.83
Intangible WIP 0 0 0 0 0
Investments 19 18.3 18.26 18.26 18.69
Loans & Advances 13.36 11.35 22.44 17.18 15.8
Other N/C Assets 1.24 62.84 1.05 46.99 3.19
Current Assets 642.65 676.64 791.74 729.65 772.98
Total Assets 855.11 945.62 1079.96 1139.69 1148.44
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 121.71 91.19 123.66 115.69 111.34
Adjustment 3.43 41.14 35.1 41.42 44.27
Changes in Assets & Liabilities -30.07 -42.64 -14.23 -75.58 -0.35
Tax Paid -31.86 -22.72 -30.47 -37.72 -29.34
Operating Cash Flow 63.22 66.97 114.05 43.81 125.92
Investing Cash Flow -60.14 -61.62 -92.28 -12.97 -109.59
Financing Cash Flow -5.83 -11.67 -12.62 -26.05 -20.76
Net Cash Flow -2.75 -6.33 9.14 4.79 -4.43

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 35.06 34.97 34.97 34.90 34.82
narsimha shibroor kamath 30.61 30.53 30.53 30.47 30.39
punita sharma 0.02 0.02 0.02 0.02 0.02
ramadas vasudev kamath. - - - 0.03 0.03
shibroor gokuldas kamath 0.01 0.01 0.01 0.01 0.01
shruti vishal rao 2.02 2.02 2.02 2.01 2.01
vibha gagan sharma 2.37 2.36 2.36 2.36 2.35
ramadas vasudev kamath hu... 0.03 0.03 0.03 - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 64.94 65.03 65.03 65.10 65.18
arian investment limited 9.44 9.42 9.42 8.96 8.79
arjun gautam ashra . 4.84 4.82 4.82 4.81 4.80
coeus global opportunitie... - - - - 1.77
gautam rasiklal ashra 2.82 2.81 2.81 2.83 2.81
gulbarga trading and inve... 5.59 5.58 5.58 5.57 5.55
investor education and pr... 2.34 - 2.39 2.38 2.38
life insurance corporatio... 6.61 6.59 6.59 6.58 6.56
llp 0.06 0.04 0.05 0.04 0.07
aspire emerging fund 2.34 2.33 2.33 1.34 -
polus global fund 1.78 1.78 1.78 1.77 -
bhupesh kumar lodha - 1.26 - - -
investor education and pr... - 2.39 - - -
fidelity puritan trust-fi... 1.82 - - - -
jainam broking limited 1.23 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Bliss GVS Pharma informs about compliance certificate 23 Nov, 2:28 PM Bliss GVS Pharma informs about disclosure 7 Nov, 5:04 PM Bliss GVS Pharma informs about disclosure 30 Oct, 12:38 PM Bliss GVS Pharma - Quaterly Results 25 Oct, 12:00 PM Bliss GVS Pharma - Quaterly Results 25 Oct, 12:00 PM Bliss GVS Pharma - Quaterly Results 24 Jul, 2:17 PM Bliss GVS Pharma - Quaterly Results 24 Jul, 2:17 PM Bliss GVS Pharma - Quaterly Results 24 Jul, 2:17 PM Bliss Gvs Pharma informs about appointment of independent director 22 Jun, 4:28 PM Bliss GVS Pharma informs about appointment of independent director 22 Jun, 3:52 PM Bliss GVS Pharma - Quaterly Results 2 May, 9:56 PM Bliss GVS Pharma - Quaterly Results 2 May, 9:56 PM Bliss GVS Pharma - Quaterly Results 23 Jan, 11:36 PM Bliss GVS Pharma - Quaterly Results 23 Jan, 11:36 PM Bliss GVS Pharma - Quaterly Results 1 Nov, 8:35 PM Bliss GVS Pharma - Quaterly Results 1 Nov, 8:35 PM Bliss GVS Pharma - Quaterly Results 1 Aug, 5:44 PM Bliss GVS Pharma - Quaterly Results 1 Aug, 5:44 PM Bliss Gvs Pharma informs about AGM outcome 19 Jul, 5:19 PM Bliss GVS Pharma gets EIR for Palghar manufacturing unit 15 Jun, 4:09 PM Bliss Gvs Pharma informs about book closure 12 May, 2:58 PM Bliss GVS Pharma - Quaterly Results 11 May, 10:48 PM Bliss GVS Pharma - Quaterly Results 11 May, 10:48 PM USFDA conducts inspections at Bliss GVS Pharma’s manufacturing unit in Palghar 20 Mar, 11:59 AM Bliss GVS Pharma informs about issuance of duplicate share certificate 18 Mar, 11:51 AM Bliss GVS Pharma informs about disclosure 1 Mar, 12:14 PM Bliss Gvs Pharma informs about disclosure 20 Feb, 3:00 PM Bliss GVS Pharma - Quaterly Results 24 Jan, 9:08 PM Bliss GVS Pharma - Quaterly Results 24 Jan, 9:08 PM BLISS GVS Pharma informs about outcome of board meeting 30 Dec, 5:16 PM Bliss GVS Pharma informs about loss of share certificate 17 Dec, 3:28 PM Bliss GVS Pharma - Quaterly Results 7 Nov, 8:05 PM Bliss GVS Pharma - Quaterly Results 7 Nov, 8:05 PM Bliss GVS Pharma - Quaterly Results 3 Aug, 8:46 PM Bliss GVS Pharma - Quaterly Results 3 Aug, 8:46 PM Bliss GVS Pharma informs about board meeting 27 Jul, 3:12 PM Bliss GVS Pharma informs about issuance of duplicate share certificates 20 Jun, 4:53 PM Bliss GVS Pharma informs about disclosure 9 Jun, 12:13 PM Bliss GVS Pharma - Quaterly Results 30 Apr, 8:46 PM Bliss GVS Pharma - Quaterly Results 30 Apr, 8:46 PM Bliss GVS Pharma informs about disclosure 4 Apr, 12:16 PM Bliss GVS Pharma informs about disclosure 1 Apr, 10:26 AM Bliss GVS Pharma informs about disclosure 22 Mar, 4:01 PM Bliss GVS Pharma informs about disclosure 16 Mar, 4:40 PM Bliss GVS Pharma receives approval of 'Certificate of GMP Compliance of a Manufacturer' from TGA 18 Feb, 4:35 PM Bliss GVS Pharma’s arm incorporates wholly owned subsidiary 29 Jan, 8:59 AM Bliss GVS Pharma informs about AGM proceedings 22 Sep, 11:59 AM Bliss GVS Pharma purchases immovable property from JMFARC 20 Sep, 9:38 AM Bliss GVS Pharma informs about details of loss of share certificate 14 Sep, 5:22 PM Bliss GVS Pharma informs about disclosure of related party transactions 10 Jun, 4:21 PM

Bliss GVS Pharma Stock Price Analysis and Quick Research Report. Is Bliss GVS Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Bliss GVS Pharma and its performance over the period of time. Bliss GVS Pharma stock price today is Rs 161.15.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Bliss GVS Pharma cash from the operating activity was Rs 125.9225 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Bliss GVS Pharma has a Debt to Equity ratio of 0.0669 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Bliss GVS Pharma , the EPS growth was -41.0552 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Bliss GVS Pharma has OPM of 17.4277330101409 % which is a good sign for profitability.
     
  • ROE: Bliss GVS Pharma have a poor ROE of 5.3064 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Bliss GVS Pharma is Rs 161.15. One can use valuation calculators of ticker to know if Bliss GVS Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Bliss GVS Pharma

Bliss GVS Pharma ABC Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Bliss GVS Pharma Limited is a leading pharmaceutical company that offers a range of products across various therapeutic segments such as antiviral, anti-malarial, antibiotic, anti-tuberculosis, and more. The company has a strong presence in both domestic and international markets with a focus on Africa, Asia, and CIS countries. With a commitment to providing high-quality, affordable healthcare solutions, Bliss GVS has become a trusted name in the pharmaceutical industry.

Bliss GVS Pharma Limited - Share Price

The share price of Bliss GVS Pharma Limited has been performing well in the past few quarters. It is an attractive option for long-term investors who are looking to invest in a growing pharmaceutical company. Our pre-built screening tools provide a detailed analysis of the share price, including trends, key market indicators, and other factors that can impact the stock's performance.

Bliss GVS Pharma Limited - Balance Sheet

The balance sheet of Bliss GVS Pharma Limited provides an overview of the company's financial health. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. The financial statements can be downloaded from our website and show a healthy financial position for the company.

Bliss GVS Pharma Limited - Annual Report

The annual report of Bliss GVS Pharma Limited provides a comprehensive overview of the company's financial performance over the year. It includes information about the company's operations, strategy, and future plans. The annual report is available for download on our website.

Bliss GVS Pharma Limited - Dividend

Bliss GVS Pharma Limited has been consistently paying dividends to its shareholders. The company has a track record of stable and increasing dividends, making it an attractive option for investors looking for a steady income stream. Our pre-built screening tools provide a detailed analysis of the company's dividend history and future prospects.

Bliss GVS Pharma Limited - Quarterly Result

The quarterly result of Bliss GVS Pharma Limited provides an update on the company's financial performance for the past quarter. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. The financial statements for the quarter can be downloaded from our website.

Bliss GVS Pharma Limited - Stock Price

The stock price of Bliss GVS Pharma Limited has been performing well in the past few quarters. It is an attractive option for long-term investors who are looking to invest in a growing pharmaceutical company. Our pre-built screening tools provide a detailed analysis of the stock price, including trends, key market indicators, and other factors that can impact the stock's performance.

Bliss GVS Pharma Limited - Price Chart

The price chart of Bliss GVS Pharma Limited provides a visual representation of the company's stock price over time. It can be used to identify trends, patterns, and key market indicators that can impact the stock's performance. Our pre-built screening tools include price charts that can be customized to suit individual investment needs.

Bliss GVS Pharma Limited - News

Our website provides up-to-date news on Bliss GVS Pharma Limited. This includes news about the company's operations, financial performance, new product launches, and other key developments. Investors can stay informed about the company's latest news and announcements through our website.

Bliss GVS Pharma Limited - Concall Transcripts

The concall transcripts of Bliss GVS Pharma Limited provide a detailed overview of the company's operations, financial performance, and other key developments. They can be downloaded from our website and provide valuable insights for long-term investors.

Bliss GVS Pharma Limited - Investor Presentations

The investor presentations of Bliss GVS Pharma Limited provide a comprehensive overview of the company's operations, strategy, and future plans. They can be downloaded from our website and provide valuable insights for long-term investors.

Bliss GVS Pharma Limited - Promoters

The promoters of Bliss GVS Pharma Limited are a key part of the company's success. They bring expertise, experience, and vision to the company, driving its growth and development. Our pre-built screening tools provide information about the company's promoters and their contribution to the company's success.

Bliss GVS Pharma Limited - Shareholders

The shareholders of Bliss GVS Pharma Limited are a key part of the company's success. They provide the necessary capital and support to drive the company's growth and development. Our pre-built screening tools provide information about the company's shareholders and their contributions to the company's success.

Note: This content is for information purposes only and does not constitute investment advice. The content is not intended to provide tax, legal, or investment advice or recommendations. The information contained herein is accurate to the best of our knowledge, but we make no guarantees that it is accurate or complete. Investors should conduct their own due diligence before making any investment decisions.

Read More
X